文献速递癫痫

安大略省耐药性癫痫儿童手术与药物治疗相关的医疗系统成本

Health Care System Costs Associated With Surgery and Medical Therapy for Children With Drug-Resistant Epilepsy in Ontario.
PubMed 文献 · Neurology · 2022-02-15

本研究基于加拿大安大略省行政数据库,比较2003至2018年在多伦多病童医院接受癫痫手术或药物治疗的耐药性癫痫儿童的长期医疗成本。手术组372例、药物组258例,手术组在术前、手术及短期护理阶段成本更高,但在中期和长期护理阶段成本更低;术后7年内手术组累计成本更高,自第8年起手术组成本更低。

要点

  • 手术组在术前、手术及术后2年内成本高于药物组,中期和长期成本低于药物组。
  • 手术组术后7年内累计成本高于药物组,自第8年起累计成本低于药物组。
  • 手术组成本最高为手术阶段,住院是成本最高的组成部分。

核心结论

  • 本研究利用真实世界数据证明,与药物治疗相比,癫痫手术对医疗系统具有长期经济益处,可支持手术的高成本。
  • 研究结果将支持未来比较激光治疗等微创治疗与手术的经济学评价。

研究设计与样本

  • 基于加拿大安大略省行政数据库的队列研究,纳入2003至2018年在多伦多病童医院接受癫痫手术评估并治疗的儿童,手术组372例、药物组258例。
  • 采用稳定权重的治疗逆概率加权平衡两组基线协变量,按治疗轨迹划分术前、手术、短期(术后前2年)、中期(术后2-5年)和长期(术后>5年)护理阶段。
  • 从医疗付费方角度评估各阶段及累计长期医疗成本,成本转换为2018年美元价值。

主要发现

  • 手术组与药物组相比,术前(3周和39周)、手术、短期护理阶段成本更高,每7患者日的归因成本分别为1602美元(95%CI 1438-1785)、172美元(95%CI 147-185)、19819美元(95%CI 18822-20932)和28美元(95%CI 22-32)。
  • 手术组与药物组相比,中期和长期护理阶段成本更低,归因成本分别为-72美元(95%CI -124至-35)和-94美元(95%CI -129至-63)。
  • 手术组成本最高为手术阶段,其次为术前护理阶段,住院是成本最高的组成部分;药物组成本从术前至长期护理阶段逐渐增加。
  • 手术组累计成本在术后前7年高于药物组,自第8年起低于药物组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Improvement in seizure control after epilepsy surgery could lead to lower health care resource use and costs, but it is uncertain whether this could offset the high costs related to surgery. This study aimed to evaluate phase-specific and cumulative long-term health care costs of surgery compared to medical therapy in children with drug-resistant epilepsy from the health care payer perspective. METHODS: Children who were evaluated for epilepsy surgery and treated with surgery or medical therapy from 2003 to 2018 at the Hospital for Sick Children in Toronto were identified from chart review and linked to their health administrative databases in Ontario, Canada. Inverse probability of treatment weighting with stabilized weights was used to balance the baseline covariates between the 2 groups. Patients were assigned to presurgery, surgery, short-term (first 2 years), intermediate-term (2-5 years), and long-term (>5 years) postsurgery care phases on the basis of treatment trajectory. Phase-specific and cumulative long-term health care costs were evaluated. Costs were converted from Canadian to US dollars year 2018 value. RESULTS: There were 372 surgical and 258 medical patients. Costs were higher in surgical than medical patients for presurgery (3 and 39 weeks), surgery, and short-term care phase, and the attributable costs of surgery per 7 patient-days were $1,602 (95% CI $1,438-$1,785), $172 (95% CI $147-$185), $19,819 (95% CI $18,822-$20,932), and $28 (95% CI $22-$32), respectively. Costs were lower in surgical patients for intermediate- and long-term care phase, and the attributable costs were -$72 (95% CI -$124 to -$35) and -$94 (95% CI -$129 to -$63), respectively. In surgical patients, costs were highest for surgery followed by presurgery care phase, with hospitalizations accounting for the highest cost component. In medical patients, costs increased gradually from presurgery to long-term care phase. Cumulative costs were higher for surgical than medical patients in the first 7 years after surgery, but from 8 years on, costs were lower for surgical patients. DISCUSSION: This study demonstrated the long-term economic benefits of epilepsy surgery compared to medical therapy for the health care system with the use of real-world data, which would justify the high costs of surgery. The results will support future economic evaluation comparing minimally invasive treatment such as laser therapy to surgery.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Widjaja E, Demoe L, Yossofzai O, et al. Health Care System Costs Associated With Surgery and Medical Therapy for Children With Drug-Resistant Epilepsy in Ontario. Neurology. 2022. PMID: 35169008. doi:10.1212/WNL.0000000000200026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。